MannKind Corporation (NASDAQ:MNKD) H.C. Wainwright 22nd Annual Global Investment Conference Call September 14, 2020 3:30 PM ET Executives Michael Castagna - Chief Executive Officer Analysts Oren Livnat - H.C. Wainwright Oren Livnat Good afternoon. Welcome back to H.C. Wainwright Twenty Second Annual Global Investment Conference. My name is Oren Livnat. I am a specialty pharmaceuticals analyst here. And I am happy to our next company. It's MannKind. With us today is CEO, Michael Castagna. I do cover the comp ...

MannKind Corporation (NASDAQ:MNKD) Q2 2020 Earnings Conference Call August 5, 2020 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steve Binder - Chief Financial Officer Conference Call Participants Dylan Dupuis - SVB Leerink Brandon Folkes - Cantor Fitzgerald Robert Hazlett - BTIG, LLC Operator Good day, everyone. Welcome to the MannKind Corporation Second Quarter 2020 Earnings Call. As a reminder, this call is being recorded on August 5, 2020, and will be available for playback ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction of inc ...

MannKind Corporation (NASDAQ:MNKD) Conference Call Summary Company Overview - MannKind Corporation is focused on developing innovative medicines for endocrine and orphan lung diseases, with a significant product called Afrezza, an inhaled insulin approved for Type 1 and Type 2 diabetes in the U.S. [4][5] - The company has partnerships with United Therapeutics, AMSL in Australia, BIOMM in Brazil, Cipla in India, and Receptor Life Sciences for international market expansion of Afrezza [5][6] Core Points and Arguments Financial Position - MannKind's financial position has improved significantly after recapitalization in August 2019, providing a runway for growth and investment [7] - The company completed three out of four milestones with United Therapeutics, receiving $12.5 million in Q2, with another $12.5 million expected in Q4 [11][12] Product Pipeline - Afrezza is the only inhaled insulin on the market, with a focus on Type 1 diabetes and pediatric patients [8][15] - The partnership with United Therapeutics is crucial for the development of Treprostinil, a treatment for pulmonary hypertension, which has the potential to expand the patient base from 3,000 to 30,000 [9][55] - The company is exploring additional products, including inhaled Tadalafil for erectile dysfunction and cannabinoids for migraines [10] Market Dynamics - The insulin market in the U.S. impacts approximately 4.5 million to 6 million Americans, with a focus on increasing Afrezza's market share [7][8] - Post-COVID, new prescriptions (NRx) trends are stabilizing, with the salesforce increasing by 19 new representatives to enhance market penetration [20][28] Technosphere Technology - MannKind's Technosphere technology allows for the delivery of various drugs via inhalation, differentiating it from other dry powder inhalation technologies [5][50] - The technology is protected by over 1,000 patents, enhancing its competitive advantage [50] Clinical Data and Efficacy - Recent studies show that Afrezza has a favorable weight profile, with patients either losing weight or gaining less compared to traditional insulin [22][24] - The company is focused on generating and publishing clinical data to improve physician and patient confidence in Afrezza [41][42] Other Important Content - The company is adapting its commercial model to focus more on Type 1 diabetes and connected care, with plans for a specialty pharmacy network and reimbursement support [46][47] - MannKind is also exploring telehealth and distribution changes to enhance efficiency and growth [36][59] - Upcoming catalysts include new data releases in August and September, as well as milestones related to the partnership with United Therapeutics [61][62] Conclusion - MannKind Corporation is positioned for growth with a strong financial foundation, innovative product pipeline, and strategic partnerships. The focus on improving market access and generating clinical data will be critical for future success.

MannKind Corporation (NASDAQ:MNKD) Q1 2020 Results Earnings Conference Call May 6, 2020 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer David Kendall - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Steven Lichtman - Oppenheimer and Company Thomas Smith - SVB Leerink Bert Hazlett - BTIG Operator Please standby, we are about to begin. Welcome to the MannKind Corporation First Quarter 2020 Earnings Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction of incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Market LLC Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission f ...